Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Avadel Pharmaceuticals PLC (AVDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AVDL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.25
1 Year Target Price $18.25
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.2% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.31B USD | Price to earnings Ratio - | 1Y Target Price 18.25 |
Price to earnings Ratio - | 1Y Target Price 18.25 | ||
Volume (30-day avg) 8 | Beta 1.63 | 52 Weeks Range 6.38 - 16.66 | Updated Date 08/15/2025 |
52 Weeks Range 6.38 - 16.66 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.03 | Actual 0.1 |
Profitability
Profit Margin -1.32% | Operating Margin (TTM) 13.04% |
Management Effectiveness
Return on Assets (TTM) -1.18% | Return on Equity (TTM) -3.63% |
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1231996126 | Price to Sales(TTM) 5.93 |
Enterprise Value 1231996126 | Price to Sales(TTM) 5.93 | ||
Enterprise Value to Revenue 5.57 | Enterprise Value to EBITDA 156.64 | Shares Outstanding 97097600 | Shares Floating 80544434 |
Shares Outstanding 97097600 | Shares Floating 80544434 | ||
Percent Insiders 4.89 | Percent Institutions 90.31 |
Upturn AI SWOT
Avadel Pharmaceuticals PLC
Company Overview
History and Background
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products. Originally an Irish company, it now operates primarily in the US. They've undergone strategic shifts, refocusing on sleep disorders.
Core Business Areas
- Narcolepsy Franchise: Development and commercialization of treatments for narcolepsy, including Xyrem (authorized generic) and FT218 (Lumryz).
Leadership and Structure
The company is led by a management team with experience in pharmaceuticals and is structured around product development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Lumryz (FT218): Once-at-bedtime oxybate for narcolepsy. Approved by FDA. Market share is growing after launch, still relatively small. Competitors: Jazz Pharmaceuticals (Xyrem, Xywav).
- Xyrem (Authorized Generic): Avadel has an authorized generic of Xyrem. Market share changes depending on market factors. Competitor: Jazz Pharmaceuticals (Xyrem, Xywav).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The narcolepsy treatment market is driven by diagnosis rates, treatment options, and pricing.
Positioning
Avadel positions itself as an innovator in narcolepsy treatment, particularly with Lumryz. Focus on patient convenience (once-nightly dosing) differentiates it.
Total Addressable Market (TAM)
The TAM for narcolepsy treatments is estimated to be in the billions. Avadel is positioned to capture a growing share with Lumryz.
Upturn SWOT Analysis
Strengths
- FDA-approved Lumryz (FT218)
- Authorized generic of Xyrem
- Focus on narcolepsy market
- Differentiated product (Lumryz's once-at-bedtime dosing)
Weaknesses
- Reliance on a limited number of products
- Competition from established players (Jazz Pharmaceuticals)
- Commercial execution risk with Lumryz launch
- Debt Levels
Opportunities
- Increasing diagnosis rates for narcolepsy
- Expanding Lumryz market share
- Developing new formulations and treatments
- Potential acquisitions or partnerships
Threats
- Generic competition for Lumryz (eventual)
- Pricing pressures and reimbursement challenges
- Regulatory changes
- Clinical trial failures for future products
Competitors and Market Share
Key Competitors
- JAZZ
Competitive Landscape
Avadelu2019s advantage lies in its Lumryz formulation. However, Jazz Pharmaceuticals has a strong established position.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to key FDA approvals and commercialization of products. Lumryz's launch is a critical driver.
Future Projections: Analyst projections vary. Consensus estimates should be consulted. Growth is expected from Lumryz.
Recent Initiatives: Lumryz commercial launch and post-marketing studies are key initiatives. Patient support programs are also important.
Summary
Avadel Pharmaceuticals is focused on the narcolepsy market, driven by Lumryz. The company faces competition from Jazz Pharmaceuticals. Success hinges on a successful Lumryz launch and market penetration. Key risks include pricing pressures and competitive dynamics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avadel Pharmaceuticals PLC's SEC Filings, Investor Relations, Third-party market research reports, Analyst reports
- JAZZ SEC Filings
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific factors can change rapidly. Information may be time sensitive and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avadel Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-07 | CEO & Director Mr. Gregory J. Divis Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 188 | Website https://www.avadel.com |
Full time employees 188 | Website https://www.avadel.com | ||
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.